Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Coherus Oncology (CHRS) Equity Average: 2014-2025

Historic Equity Average for Coherus Oncology (CHRS) over the last 11 years, with Sep 2025 value amounting to $103.8 million.

  • Coherus Oncology's Equity Average rose 220.64% to $103.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $103.8 million, marking a year-over-year increase of 220.64%. This contributed to the annual value of -$162.7 million for FY2024, which is 1.64% up from last year.
  • As of Q3 2025, Coherus Oncology's Equity Average stood at $103.8 million, which was up 426.20% from -$31.8 million recorded in Q2 2025.
  • Coherus Oncology's Equity Average's 5-year high stood at $204.3 million during Q1 2021, with a 5-year trough of -$185.6 million in Q2 2023.
  • Over the past 3 years, Coherus Oncology's median Equity Average value was -$137.6 million (recorded in 2024), while the average stood at -$106.6 million.
  • Per our database at Business Quant, Coherus Oncology's Equity Average slumped by 3,588.37% in 2023 and then soared by 220.64% in 2025.
  • Quarterly analysis of 5 years shows Coherus Oncology's Equity Average stood at $114.2 million in 2021, then plummeted by 202.65% to -$117.3 million in 2022, then slumped by 39.43% to -$163.5 million in 2023, then soared by 32.74% to -$110.0 million in 2024, then spiked by 220.64% to $103.8 million in 2025.
  • Its Equity Average was $103.8 million in Q3 2025, compared to -$31.8 million in Q2 2025 and -$157.7 million in Q1 2025.